Authors
Latest:
Regorafenib Shows High Anti-Tumor Activity as Monotherapy in Advanced, Pre-Treated Thymic CancerAs part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.
Latest:
Dr. Darren Feldman on Treating Patients Who Develop Neutropenic Fever​Darren Feldman, MD, assistant attending physician for the Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how to properly treat neutropenic fever as a toxicity stemming from chemotherapy treatment.
Latest:
Expected Findings of the SWOG S1505 Trial in Pancreatic CancerDavendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Latest:
The Inadequacy of the Current Standard of Care for GlioblastomaDavid A. Reardon, MD, clinical director, center for neuro-oncology, Dana-Farber Cancer Institute, discusses the inadequacy of the current standard of care in glioblastoma (GBM).
Latest:
Guidelines Consider Use of Targeted Therapies in Colorectal CancerThe use of targeted therapies in colon cancer has become increasingly important, with several options available for clinicans to choose between. In a review of recent updates incorporating molecularly targeted therapy use in the National Comprehensive Cancer Network guidelines, the evidence for these new recommendations are detailed in support of their use in patients with colon cancer.
Latest:
Novel Treatment Approaches in Relapsed/Refractory Mantle Cell LymphomaManagement of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.
Latest:
Nanovesicles as Targeted Therapy for Lung CancerAvailable therapies for patients with lung cancer are associated with a number of significant toxicities that must be effectively managed by oncologists.
Latest:
Dr. Metz on Somatostatin Analogs and Emerging Agents in NETs LandscapeDavid C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).
Latest:
Nivolumab Shows Promise Versus Docetaxel for NSCLC in Checkmate 057 TrialDavid Carbone, MD, PhD, professor, internal medicine, College of Medicine Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute at Ohio State University Medical Centerdiscusses the Checkmate 057 trial, which evaluates Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Latest:
PD-L1 Expression in Non-Clear Cell Renal Cell CancerDavid F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Latest:
Preparing Cancer Centers for Outpatient CAR T-cell AdministrationDavid G. Maloney, MD, PhD, reviews the protocols and infrastructure necessary to deliver chimeric antigen receptor T-cell therapy to patients receiving treatment in the outpatient setting.
Latest:
Strategies for Overcoming <em>KRAS</em> Mutations in Lung CancerDavid Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.
Latest:
KEYNOTE-062 Highlights Role of Pembrolizumab in Gastric/GEJ Cancer SubtypesDavid H. Ilson, MD, PhD, discusses the current role of pembrolizumab in patients with gastric cancer or gastroesophageal junction adenocarcinoma based on the results from the KEYNOTE-062 trial.
Latest:
What’s Next With Next-Generation BRAF Inhibitors?Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.
Latest:
Efficacy Results for LOXO-101 in TRK Fusion CancersDavid Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Latest:
Exploring Current and Upcoming Therapies for Hepatocellular CarcinomaDavid J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Latest:
Dr. Stewart on the Impact of Delaying Approval on Overall SurvivalDavid J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.
Latest:
Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLDavid J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
Latest:
The Need to Study Tissue BiomarkersDavid L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
Latest:
tttPharmacist Glycemic Control Team Associated With Improved Perioperative Glycemic and Utilization OutcomesImplementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.
Latest:
Recognizing Immunotherapy Side Effects in the Community SettingDavid M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice. <br />
Latest:
Expert Addresses Major Challenge in Treatment of MyelomaDavid M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Latest:
How CAR T Cells Can Change the Treatment Landscape for Non-Hodgkin LymphomaDavid Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Latest:
KTE-X19 Shows Efficacy as Treatment of MCL in the ZUMA-2 TrialDavid Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
Latest:
CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCLDavid Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.
Latest:
Managing Known CAR T-Cell Toxicities With KTE-X19David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.
Latest:
Long Duration of Response Seen for Pembrolizumab in Endometrial CancerDavid O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.
Latest:
The Accuracy and Availability of Genetic Testing for Lung CancerDavid P. Carbone, MD, PhD, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.
